Curcumin enhances the response of non-Hodgkin's lymphoma cells to ionizing radiation through further induction of cell cycle arrest at the G2/M phase and inhibition of mTOR phosphorylation

Qiao,Qiao; Jiang,Yuanjun; Li,Guang

doi:10.3892/or.2012.2091

Curcumin enhances the response of non-Hodgkin's lymphoma cells to ionizing radiation through further induction of cell cycle arrest at the G2/M phase and inhibition of mTOR phosphorylation

Authors:
- Qiao Qiao
- Yuanjun Jiang
- Guang Li
View Affiliations

Affiliations: Department of Radiotherapy, The First Hospital of China Medical University, Shenyang 110001, P.R. China, Department of Urology, The First Hospital of China Medical University, Shenyang 110001, P.R. China
Published online on: October 19, 2012 https://doi.org/10.3892/or.2012.2091
Pages: 380-386

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Abstract. It is crucial to enhance tumor radiosensitivity for the purpose of both lowering the dose of ionizing radiation (IR) and achieving higher antitumor efficacy. We identified curcumin as a radiosensitizer to enhance non-Hodgkin's lymphoma (NHL) cell response to IR in vitro and further investigated the mechanism mediating this effect. We treated Namalwa, Ramos and Raji cell lines with vehicle, curcumin, IR and curcumin-IR. Cell viability and cell cycle distribution were determined to ascertain the radiosensitization effect of curcumin. DNA damage-related proteins, cell cycle regulatory proteins, phosphorylation of mammalian target of rapamycin (mTOR) and the nuclear translocation of the downstream nuclear factor-κB (NF-κB) target were examined by western blotting. Treatment with curcumin led to decreased viability of all three types of NHL cells and had a profound radiosensitization effect. Pre-treatment with curcumin at a low concentration of 2 µmol/l increased IR-induced G2/M arrest in the cell cycle and increased the expression of cyclin-dependent kinase inhibitors, p21cip1 and p53. However, this effect was blocked when NHL cells were pre-treated with 10 µmol/l of KU55933, a specific inhibitor of ataxia-telangiectasia-mutated (ATM). Pre-treatment with curcumin inhibited the phosphorylation of mTOR and the nuclear translocation of the downstream NF-κB target induced by IR. Curcumin enhanced the cell response to IR in NHL mediated through the induction of G2/M phase arrest and the inhibition of both a constitutive and IR-induced activation of the mTOR-NF-κB pathway. This offers great potential for curcumin to be used in conjunction with radiotherapy for NHL in order to increase the efficiency of the treatment.

View Figures

View References

1	Bulut E, Bekcioglu B, Gunhan O and Sener I: Diffuse large B-cell lymphoma with oral manifestations. J Craniofac Surg. 22:1144–1147. 2011. View Article : Google Scholar : PubMed/NCBI
2	Hainsworth JD: Monoclonal antibody therapy in lymphoid malignancies. Oncologist. 5:376–384. 2000. View Article : Google Scholar : PubMed/NCBI
3	Li L, Aggarwal BB, Shishodia S, Abbruzzese J and Kurzrock R: Nuclear factor-kappaB and IkappaB kinase are constitutively active in human pancreatic cells, and their down-regulation by curcumin (diferuloylmethane) is associated with the suppression of proliferation and the induction of apoptosis. Cancer. 101:2351–2362. 2004. View Article : Google Scholar
4	Aggarwal BB, Banerjee S, Bharadwaj U, Sung B, Shishodia S and Sethi G: Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem Pharmacol. 73:1024–1032. 2007. View Article : Google Scholar
5	Liu HL, Chen Y, Cui GH and Zhou JF: Curcumin, a potent anti-tumor reagent, is a novel histone deacetylase inhibitor regulating B-NHL cell line Raji proliferation. Acta Pharmacol Sin. 26:603–609. 2005. View Article : Google Scholar : PubMed/NCBI
6	Alaikov T, Konstantinov SM, Tzanova T, Dinev K, Topashka-Ancheva M and Berger MR: Antineoplastic and anticlastogenic properties of curcumin. Ann NY Acad Sci. 1095:355–370. 2007. View Article : Google Scholar : PubMed/NCBI
7	Syng-Ai C, Kumari AL and Khar A: Effect of curcumin on normal and tumor cells: role of glutathione and bcl-2. Mol Cancer Ther. 3:1101–1108. 2004.PubMed/NCBI
8	Khafif A, Lev-Ari S, Vexler A, et al: Curcumin: a potential radio-enhancer in head and neck cancer. Laryngoscope. 119:2019–2026. 2009. View Article : Google Scholar : PubMed/NCBI
9	Chendil D, Ranga RS, Meigooni D, Sathishkumar S and Ahmed MM: Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. Oncogene. 23:1599–1607. 2004. View Article : Google Scholar : PubMed/NCBI
10	Sandur SK, Deorukhkar A, Pandey MK, et al: Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity. Int J Radiat Oncol Biol Phys. 75:534–542. 2009. View Article : Google Scholar : PubMed/NCBI
11	Yallapu MM, Maher DM, Sundram V, Bell MC, Jaggi M and Chauhan SC: Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J Ovarian Res. 3:112010. View Article : Google Scholar : PubMed/NCBI
12	Javvadi P, Segan AT, Tuttle SW and Koumenis C: The chemopreventive agent curcumin is a potent radiosensitizer of human cervical tumor cells via increased reactive oxygen species production and overactivation of the mitogen-activated protein kinase pathway. Mol Pharmacol. 73:1491–1501. 2008. View Article : Google Scholar
13	Qiao Q, Jiang Y and Li G: Curcumin improves the antitumor effect of X-ray irradiation by blocking the NF-kappaB pathway: an in vitro study of lymphoma. Anticancer Drugs. 23:597–605. 2012. View Article : Google Scholar : PubMed/NCBI
14	Anand P, Sung B, Kunnumakkara AB, Rajasekharan KN and Aggarwal BB: Suppression of pro-inflammatory and proliferative pathways by diferuloylmethane (curcumin) and its analogues dibenzoylmethane, dibenzoylpropane, and dibenzylideneacetone: role of Michael acceptors and Michael donors. Biochem Pharmacol. 82:1901–1909. 2011. View Article : Google Scholar
15	Wang Y, Rishi AK, Wu W, et al: Curcumin suppresses growth of mesothelioma cells in vitro and in vivo, in part, by stimulating apoptosis. Mol Cell Biochem. 357:83–94. 2011. View Article : Google Scholar : PubMed/NCBI
16	Lev-Ari S, Starr A, Vexler A, et al: Inhibition of pancreatic and lung adenocarcinoma cell survival by curcumin is associated with increased apoptosis, down-regulation of COX-2 and EGFR and inhibition of Erk1/2 activity. Anticancer Res. 26:4423–4430. 2006.PubMed/NCBI
17	Liao S, Xia J, Chen Z, et al: Inhibitory effect of curcumin on oral carcinoma CAL-27 cells via suppression of Notch-1 and NF-kappaB signaling pathways. J Cell Biochem. 112:1055–1065. 2011. View Article : Google Scholar : PubMed/NCBI
18	Binion DG, Otterson MF and Rafiee P: Curcumin inhibits VEGF-mediated angiogenesis in human intestinal microvascular endothelial cells through COX-2 and MAPK inhibition. Gut. 57:1509–1517. 2008. View Article : Google Scholar : PubMed/NCBI
19	Huang S and Houghton PJ: Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol. 3:371–377. 2003. View Article : Google Scholar
20	Li R, Wang R, Zhai R and Dong Z: Targeted inhibition of mammalian target of rapamycin (mTOR) signaling pathway inhibits proliferation and induces apoptosis of laryngeal carcinoma cells in vitro. Tumori. 97:781–786. 2011.PubMed/NCBI
21	Jazirehi AR, Wenn PB and Damavand M: Therapeutic implications of targeting the PI3Kinase/AKT/mTOR signaling module in melanoma therapy. Am J Cancer Res. 2:178–191. 2012.PubMed/NCBI
22	Chakraborty S, Mohiyuddin SM, Gopinath KS and Kumar A: Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma. BMC Cancer. 8:1632008. View Article : Google Scholar : PubMed/NCBI
23	Darb-Esfahani S, Faggad A, Noske A, et al: Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro. J Cancer Res Clin Oncol. 135:933–941. 2009. View Article : Google Scholar : PubMed/NCBI
24	Ekstrand AI, Jonsson M, Lindblom A, Borg A and Nilbert M: Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer. Fam Cancer. 9:125–129. 2010. View Article : Google Scholar : PubMed/NCBI
25	Kuo SH, Hsu CH, Chen LT, et al: Lack of compensatory pAKT activation and eIF4E phosphorylation of lymphoma cells towards mTOR inhibitor, RAD001. Eur J Cancer. 47:1244–1257. 2011. View Article : Google Scholar : PubMed/NCBI
26	Beevers CS, Chen L, Liu L, Luo Y, Webster NJ and Huang S: Curcumin disrupts the mammalian target of rapamycin-raptor complex. Cancer Res. 69:1000–1008. 2009. View Article : Google Scholar : PubMed/NCBI
27	Scapagnini G, Foresti R, Calabrese V, Giuffrida Stella AM, Green CJ and Motterlini R: Caffeic acid phenethyl ester and curcumin: a novel class of heme oxygenase-1 inducers. Mol Pharmacol. 61:554–561. 2002. View Article : Google Scholar : PubMed/NCBI
28	Kumar R and Atlas I: Interferon alpha induces the expression of retinoblastoma gene product in human Burkitt lymphoma Daudi cells: role in growth regulation. Proc Natl Acad Sci USA. 89:6599–6603. 1992. View Article : Google Scholar : PubMed/NCBI
29	Neijenhuis S, Verwijs-Janssen M, van den Broek LJ, Begg AC and Vens C: Targeted radiosensitization of cells expressing truncated DNA polymerase β. Cancer Res. 70:8706–8714. 2010.PubMed/NCBI
30	Shrivastav M, Miller CA, De Haro LP, et al: DNA-PKcs and ATM co-regulate DNA double-strand break repair. DNA Repair (Amst). 8:920–929. 2009. View Article : Google Scholar : PubMed/NCBI
31	Lukas C, Bartkova J, Latella L, et al: DNA damage-activated kinase Chk2 is independent of proliferation or differentiation yet correlates with tissue biology. Cancer Res. 61:4990–4993. 2001.PubMed/NCBI
32	Huang M, Miao ZH, Zhu H, Cai YJ, Lu W and Ding J: Chk1 and Chk2 are differentially involved in homologous recombination repair and cell cycle arrest in response to DNA double-strand breaks induced by camptothecins. Mol Cancer Ther. 7:1440–1449. 2008. View Article : Google Scholar
33	Hickson I, Zhao Y, Richardson CJ, et al: Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 64:9152–9159. 2004. View Article : Google Scholar : PubMed/NCBI
34	Rashid A, Liu C, Sanli T, et al: Resveratrol enhances prostate cancer cell response to ionizing radiation. Modulation of the AMPK, Akt and mTOR pathways. Radiat Oncol. 6:1442011. View Article : Google Scholar : PubMed/NCBI
35	Kunnumakkara AB, Anand P and Aggarwal BB: Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett. 269:199–225. 2008. View Article : Google Scholar
36	Sahu RP, Batra S and Srivastava SK: Activation of ATM/Chk1 by curcumin causes cell cycle arrest and apoptosis in human pancreatic cancer cells. Br J Cancer. 100:1425–1433. 2009. View Article : Google Scholar : PubMed/NCBI
37	Taylor WR and Stark GR: Regulation of the G2/M transition by p53. Oncogene. 20:1803–1815. 2001. View Article : Google Scholar : PubMed/NCBI
38	Calaf GM, Echiburu-Chau C, Wen G, Balajee AS and Roy D: Effect of curcumin on irradiated and estrogen-transformed human breast cell lines. Int J Oncol. 40:436–442. 2012.PubMed/NCBI
39	Lin YC, Chen HW, Kuo YC, Chang YF, Lee YJ and Hwang JJ: Therapeutic efficacy evaluation of curcumin on human oral squamous cell carcinoma xenograft using multimodalities of molecular imaging. Am J Chin Med. 38:343–358. 2010. View Article : Google Scholar : PubMed/NCBI
40	Moragoda L, Jaszewski R and Majumdar AP: Curcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cells. Anticancer Res. 21:873–878. 2001.PubMed/NCBI
41	Liu E, Wu J, Cao W, et al: Curcumin induces G2/M cell cycle arrest in a p53-dependent manner and upregulates ING4 expression in human glioma. J Neurooncol. 85:263–270. 2007. View Article : Google Scholar : PubMed/NCBI
42	Schiewer MJ, Den R, Hoang DT, et al: mTOR is a selective effector of the radiation therapy response in androgen receptor-positive prostate cancer. Endocr Relat Cancer. 19:1–12. 2012. View Article : Google Scholar : PubMed/NCBI
43	Johnson SM, Gulhati P, Arrieta I, et al: Curcumin inhibits proliferation of colorectal carcinoma by modulating Akt/mTOR signaling. Anticancer Res. 29:3185–3190. 2009.PubMed/NCBI
44	Beevers CS, Li F, Liu L and Huang S: Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells. Int J Cancer. 119:757–764. 2006. View Article : Google Scholar : PubMed/NCBI